Celecoxib Solution Suppliers & Bulk Manufacturers

Available Forms: Oral Solution

Available Strengths: 25 mg/mL

Reference Brands: Elyxyb(U.S)

Category: Analgesic

Celecoxib Oral Solution, A selective COX-2 inhibitor used for the treatment of acute migraine and pain. Available as 25 mg/mL (120 mg/4.8 mL) oral solution, it offers rapid relief with improved patient compliance, especially for those who have difficulty swallowing capsules. Celecoxib solution is available in Oral Solution and strengths such as 25 mg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Celecoxib solution is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Celecoxib solution can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that possesses anti-inflammatory, analgesic, and antipyretic properties. It is commonly prescribed for the management of conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain. By reducing inflammation, swelling, and joint stiffness, celecoxib helps improve mobility and overall quality of life in patients suffering from chronic musculoskeletal and inflammatory disorders.

Celecoxib works by selectively inhibiting the cyclooxygenase-2 (COX-2) enzyme, which plays a key role in the synthesis of prostaglandins responsible for pain and inflammation in the body. Unlike many traditional NSAIDs that inhibit both COX-1 and COX-2 enzymes, celecoxib specifically targets COX-2. This selective inhibition helps provide effective anti-inflammatory and pain-relieving effects while reducing the risk of serious gastrointestinal side effects commonly associated with non-selective NSAIDs.

In addition to its use in pain and inflammatory conditions, celecoxib has also been studied for its potential role in reducing the formation of adenomatous colorectal polyps in patients with familial adenomatous polyposis (FAP), a hereditary condition associated with an increased risk of colorectal cancer. Due to its targeted mechanism of action and therapeutic effectiveness, celecoxib remains an important option in the treatment of inflammatory and pain-related conditions.